Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Innovation Pharmaceuticals Inc.
Innovation Pharmaceuticals Inc. News
May 20, 2024 - https://www.businesswire.com
INVNT™ Announced as Sponsor and Co-Producer of Discovery Stage at SXSW Sydney® 2024
Aug 28, 2023 - globenewswire.com
Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024
Jun 18, 2021 - globenewswire.com
Innovation Pharma Announces New Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presented at the 2021 Military Health System Research Symposium
May 27, 2021 - globenewswire.com
Patient Enrollment Reaches 90 Percent in Innovation Pharmaceuticals Phase 2 Clinical Trial of Brilacidin for COVID-19
Innovation Pharmaceuticals Inc. Quantitative Score
About Innovation Pharmaceuticals Inc.
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company is also developing Kevetrin, an anti-cancer compound for treating ovarian cancer. It has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.
Innovation Pharmaceuticals Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Innovation Pharmaceuticals Inc. Financials
Table Compare
Compare IPIX metrics with: | |||
|---|---|---|---|
Earnings & Growth | IPIX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | IPIX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | IPIX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | IPIX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Innovation Pharmaceuticals Inc. Income
Innovation Pharmaceuticals Inc. Balance Sheet
Innovation Pharmaceuticals Inc. Cash Flow
Innovation Pharmaceuticals Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Innovation Pharmaceuticals Inc. Executives
| Name | Role |
|---|---|
| Mr. Leo Ehrlich CPA | Chairman, Chief Executive Officer, Chief Financial Officer, Principal Accounting Officer & Secretary |
| Ms. Jane Harness M.S., MP | Senior Vice President of Clinical Sciences & Portfolio Management |
| Mr. Jim Boeheim | Business Advisor |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Leo Ehrlich CPA | Chairman, Chief Executive Officer, Chief Financial Officer, Principal Accounting Officer & Secretary | Male | 1958 | 515.85K |
| Ms. Jane Harness M.S., MP | Senior Vice President of Clinical Sciences & Portfolio Management | Female | 1968 | 275K |
| Mr. Jim Boeheim | Business Advisor | Male | -- |
Innovation Pharmaceuticals Inc. Insider Trades
| Date | 30 Dec |
| Name | EHRLICH LEO |
| Role | CEO and Chairman |
| Transaction | Disposed |
| Type | J-Other |
| Shares | 11307527 |
| Date | 1 Sep |
| Name | Harness Jane A. |
| Role | Vice President |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 1000 |
| Date | 1 Sep |
| Name | Harness Jane A. |
| Role | Vice President |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 58394 |
| Date | 11 Sep |
| Name | Harness Jane A. |
| Role | Vice President |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 21606 |
| Date | 11 Sep |
| Name | Harness Jane A. |
| Role | Vice President |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 58394 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 30 Dec | EHRLICH LEO | CEO and Chairman | Disposed | J-Other | 11307527 |
| 1 Sep | Harness Jane A. | Vice President | Disposed | F-InKind | 1000 |
| 1 Sep | Harness Jane A. | Vice President | Acquired | A-Award | 58394 |
| 11 Sep | Harness Jane A. | Vice President | Disposed | F-InKind | 21606 |
| 11 Sep | Harness Jane A. | Vice President | Acquired | A-Award | 58394 |